|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00142155 |
|
Date of registration:
|
01/09/2005 |
|
Primary sponsor: |
|
|
Public title:
|
Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia
|
|
Scientific title:
|
Correlation of Fc Gamma RIIIA Receptor Expression and Response to Rituximab and Other Monoclonal Antibodies in Patients With Waldenstrom's Macroglobulinemia |
|
Date of first enrolment:
|
January 2002 |
|
Target sample size:
|
300 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00142155 |
|
Study type:
|
Interventional |
|
Study design:
|
N/A
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
Steven Treon, MD, MA, PhD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Dana-Farber Cancer Institute |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Patients treated with rituximab or other monoclonal antibodies for Waldenstrom's
macroglobulinemia
Age minimum:
30 Years
Age maximum:
90 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Waldenstrom's Macroglobulinemia
|
|
Intervention(s)
|
|
Drug: monoclonal antibodies
|
|
Drug: Rituximab
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|